Form 4 for BBIO BridgeBio Pharma, Inc.
Accepted 2025-12-16 00:00:00 ET · period of report 2025-12-12 · accession 0001470831-25-000422 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-16 | 2025-12-12 | BBIO | Kumar Neil | CEO, Dir | M - OptEx | — | +61.0K | 289.8K | +27% | — |
| DM | 2025-12-16 | 2025-12-15 | BBIO | Kumar Neil | CEO, Dir | S - Sale+OE | $74.64 | -30.0K | 230.5K | -12% | -$2.24M |
| D | 2025-12-16 | 2025-12-12 | BBIO | Kumar Neil | CEO, Dir | F - Tax | $75.15 | -31.0K | 258.8K | -11% | -$2.33M |
| D | 2025-12-16 | 2025-12-12 | BBIO | Kumar Neil | CEO, Dir | M - OptEx | $0.00 | -61.0K | 61.0K | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-12 | M | A | 60,975 | — | 289,751 | D | — | — | (F1) Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. |
| 2 | Common | Common Stock | 2025-12-15 | S | D | 1,700 | $75.24 | 228,776 | D | — | — | (F5) Represents the weighted average sale price of the shares sold from $75.13 to $75.49 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2025-12-15 | S | D | 28,311 | $74.60 | 230,476 | D | — | — | (F4) Represents the weighted average sale price of the shares sold from $74.12 to $75.11 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2025-12-12 | F | D | 30,964 | $75.15 | 258,787 | D | — | — | (F2) Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 60,975 shares of Common Stock underlying the Reporting Person's RSUs. |
| 5 | Derivative | Restricted Stock Units | 2025-12-12 | M | D | 60,975 | $0.00 | 60,976 | D | — · — to — | 60,975 Common Stock | (F1) Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. (F7) The RSUs vest with respect to 1/2 of the underlying shares on December 12, 2025. Thereafter, the remaining underlying shares shall vest on December 12, 2026, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. |